To avoid undesired inflammation, they administered treatment with synthetic diABZI STING agonists at the early stage of infection and sufficiently slowed the SARS-CoV-2 invasion in mice [141], suggesting that STING agonist adjuvant vaccines should be used as early treatment to obtain the most effective protection against SARS-CoV-2. This evidence concerns the gene STING1 and infection.